ImmunoPrecise Antibodies divests Netherlands facilities to AVS Bio

2025-08-06 20:42

ImmunoPrecise Antibodies (NASDAQ:IPA) announced on Wednesday the successful sale of its Netherlands-based subsidiary, ImmunoPrecise Antibodies to AVS Bio for a total enterprise value of $12M.
AVS Bio, a portfolio company of Arlington Capital Partners, is a global provider of critical inputs and services for the bioprocessing and biologics industries. The transaction generated $11.7M USD in net proceeds on a cash-free, debt-free basis.
The proceeds will support investment in scientific platforms, data-driven discovery technologies, and expansion of key strategic programs, the company said.
The sale was conducted through a competitive, arm’s-length process.
A 12-month Transition Services Agreement will provide continuity across key functions during the transition. IPA holds no material ongoing relationship with AVS Bio or its affiliates beyond the scope of the transaction.
Shares of ImmunoPrecise Antibodies (NASDAQ:IPA) were up more than 4% in premarket trading.

More on ImmunoPrecise